Technical Analysis for MLTX - MoonLake Immunotherapeutics
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 20 DMA Support | Bullish | 4.74% | |
| Crossed Above 50 DMA | Bullish | 4.74% | |
| MACD Bullish Signal Line Cross | Bullish | 4.74% | |
| Multiple of Ten Bullish | Other | 4.74% | |
| Outside Day | Range Expansion | 4.74% | |
| Up 3 Days in a Row | Strength | 4.74% | |
| 50 DMA Resistance | Bearish | 9.03% |
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | about 13 hours ago |
| Up 5% | about 15 hours ago |
| Rose Above Upper Bollinger Band | about 16 hours ago |
| Up 1 ATR | about 16 hours ago |
| Up 3% | about 16 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, the first investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients. Sonelokimab optimally inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. The Company’s focus is on inflammatory diseases with a major unmet need with lead indications currently progressing into Phase 2 trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis or radiographic axial spondyloarthritis. MoonLake is headquartered in Zug, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Organ Systems Autoimmune Disease Inflammation Inflammatory Diseases Arthritis Rheumatology Psoriatic Arthritis Hidradenitis Suppurativa Interleukin 17 Interleukins Spondylitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Organ Systems Autoimmune Disease Inflammation Inflammatory Diseases Arthritis Rheumatology Psoriatic Arthritis Hidradenitis Suppurativa Interleukin 17 Interleukins Spondylitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 64.98 |
| 52 Week Low | 37.55 |
| Average Volume | 329,629 |
| 200-Day Moving Average | 46.83 |
| 50-Day Moving Average | 50.11 |
| 20-Day Moving Average | 49.82 |
| 10-Day Moving Average | 51.20 |
| Average True Range | 2.45 |
| RSI (14) | 61.98 |
| ADX | 16.29 |
| +DI | 30.27 |
| -DI | 15.67 |
| Chandelier Exit (Long, 3 ATRs) | 47.58 |
| Chandelier Exit (Short, 3 ATRs) | 52.59 |
| Upper Bollinger Bands | 54.62 |
| Lower Bollinger Band | 45.02 |
| Percent B (%b) | 0.97 |
| BandWidth | 19.28 |
| MACD Line | 0.75 |
| MACD Signal Line | 0.45 |
| MACD Histogram | 0.3039 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 59.58 | ||||
| Resistance 3 (R3) | 59.20 | 57.06 | 58.70 | ||
| Resistance 2 (R2) | 57.06 | 55.72 | 57.25 | 58.41 | |
| Resistance 1 (R1) | 55.69 | 54.90 | 56.38 | 56.07 | 58.12 |
| Pivot Point | 53.56 | 53.56 | 53.90 | 53.75 | 53.56 |
| Support 1 (S1) | 52.19 | 52.22 | 52.87 | 52.57 | 50.52 |
| Support 2 (S2) | 50.05 | 51.39 | 50.24 | 50.23 | |
| Support 3 (S3) | 48.68 | 50.05 | 49.94 | ||
| Support 4 (S4) | 49.06 |
